Overweight Treatment Market Set for 7.9% CAGR Growth Through 2032, Says Persistence Market Research

The global overweight treatment market is experiencing a significant upswing, driven by a convergence of healthcare challenges and rising public awareness about the health risks associated with obesity. As of 2021, the market was valued at US$ 32.8 Bn, and according to Persistence Market Research, it is expected to grow at a CAGR of 7.9%, reaching US$ 75.1 Bn by 2032. The surge in obesity rates worldwide-now classified as a public health epidemic-has spurred demand for effective treatments, including medications, supplements, surgical interventions, and lifestyle management programs.

Among the segments, supplements are expected to be the leading contributor, projected to reach US$ 68.7 Bn by 2032. On the regional front, North America, led by the United States, dominates the global overweight treatment market. This is primarily due to the high prevalence of obesity-related comorbidities, robust healthcare infrastructure, and consumer willingness to adopt new weight-loss therapies. The U.S. alone held 91.1% of the North American market share in 2021, indicating its central role in the industry's expansion.

✅ Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/33086

Key Highlights from the Report:

✦ The global overweight treatment market is projected to grow at a CAGR of 7.9% from 2022 to 2032.
✦ Supplements are forecasted to dominate the market, reaching a valuation of US$ 68.7 Bn by 2032.
✦ Liraglutide captured 65.2% of the drug treatment market in 2021, due to its high efficacy.
✦ China is poised to contribute over 40% of East Asia's market share, driven by lifestyle changes.
✦ Institutional sales channels, particularly hospitals, accounted for 58.2% of global market share.
✦ Germany is projected to expand at a CAGR of 8.3%, driven by increasing Type-1 diabetes prevalence.

Market Segmentation

The overweight treatment market is segmented based on treatment type, distribution channel, and end-user applications. By treatment, the market includes drugs, dietary supplements, and surgical solutions. Among drug treatments, Liraglutide has emerged as a clear leader, commanding over 65% of the market in 2021, due to its strong bioavailability and effectiveness in appetite suppression.

On the distribution channel front, the market is divided into institutional and retail sales. Institutional channels, especially hospitals, account for the largest market share due to comprehensive diagnostic facilities, skilled healthcare professionals, and the availability of integrated treatment services. Hospitals provide pharmacotherapy, diet counselling, and behavioral support, making them a preferred choice for overweight individuals.

Regional Insights

Geographically, North America leads the market, with the U.S. accounting for a major portion. The country's high obesity prevalence and health awareness levels have fueled demand for both clinical and at-home treatment options.

Germany, within Europe, is witnessing growth thanks to national campaigns and increased investment in research and treatment infrastructure. The German Obesity Alliance is playing a crucial role in encouraging prevention and effective management of overweight conditions.

China is projected to be the fastest-growing market in East Asia, driven by a rapid shift toward Western lifestyles, processed food consumption, and decreased physical activity. Government health initiatives and increased acceptance of medical weight-loss interventions further support this growth.

In India, rapid urbanization and sedentary work culture have led to rising obesity levels, especially among youth. Government schemes like the Fit India Movement and insurance coverage for bariatric surgeries are positively impacting market dynamics in South Asia.

Market Drivers

Several key drivers are accelerating the growth of the overweight treatment market. First and foremost is the rising global incidence of obesity, which is now considered a risk factor for numerous chronic diseases including diabetes, cardiovascular conditions, and even certain cancers. According to the WHO, more than 1.9 billion adults were overweight in 2016, and the numbers have only risen since.

The COVID-19 pandemic acted as a wake-up call for many, as obese individuals were found to be at greater risk of severe outcomes. This has spurred a wave of public health campaigns and personal awareness initiatives. Moreover, regulatory cooperation, such as the USFDA Safety Innovations Act, has streamlined drug approvals, encouraging pharmaceutical innovation and faster market entry for effective treatments.

Market Restraints

Despite its strong growth potential, the market faces some significant hurdles. The high cost of drug development and surgical interventions can deter many individuals, especially in low- and middle-income countries. Research and clinical trials require substantial financial investment and time, which delays the launch of innovative treatments.

Another critical concern is drug safety. Several anti-obesity drugs have been withdrawn from the market due to serious side effects, including cancer risks. For instance, the FDA pulled Belviq (Lorcaserin) due to its association with cancer. Such safety concerns limit consumer trust and complicate regulatory approvals, acting as a barrier to market growth.

✅ Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/33086

Market Opportunities

The overweight treatment industry is ripe with opportunities, particularly in the realm of biologic drugs and personalized medicine. The use of single-agent antibody drugs for weight loss shows promising results in terms of therapeutic efficacy and fewer side effects. Drugs like Liraglutide and other GLP-1 analogs are examples of how precision medicine is transforming the landscape.

Moreover, increasing partnerships between public health institutions and private sector innovators are fostering research and expanding market access. There's also significant potential in emerging markets like India and China, where rising urban populations and changing diets are creating a vast consumer base for new products and services.

✔ Reasons to Buy the Report:

✔ Gain a comprehensive understanding of global and regional market trends and forecasts through 2032.
✔ Identify key drivers, restraints, and opportunities shaping the overweight treatment market landscape.
✔ Understand competitive positioning and strategies of top market players through detailed company profiles.
✔ Benefit from in-depth segmentation analysis across treatment types, distribution channels, and geography.
✔ Access insights into ongoing clinical research, regulatory developments, and emerging technologies.

Company Insights

• Novo Nordisk A/S
• VIVUS LLC
• AstraZeneca
• Currax Pharmaceuticals LLC
• Spansules Pharmatech Pvt Ltd
• Atkins Nutritional Inc
• Apollo Endosurgery, Inc
• Herbalife Nutrition Ltd.
• SMP Nutra
• Allurion Technologies
• ReShape Lifesciences, Inc
• Bariatric Solutions GmbH
• Silimed
• ENDALIS
• Districlass Medical
• Medtronic

Recent Developments:
• ReShape LifeSciences Inc. merged with Obalon Therapeutics in June 2021 to strengthen their combined product offerings in physician-led weight loss.
• Currax Pharmaceuticals launched the "Why Weight: Communicate" initiative in 2021, encouraging patients to engage healthcare providers in weight management discussions.

Conclusion

The global overweight treatment market is poised for robust growth, underpinned by rising obesity rates, improved awareness, and technological advancements in therapeutic solutions. As countries grapple with the health implications of sedentary lifestyles and unhealthy diets, demand for effective weight-loss solutions will only intensify. North America leads the charge, while emerging economies in Asia-Pacific are set to be the next growth frontiers. With regulatory support and increasing investment in drug discovery and weight-loss technologies, the industry offers compelling opportunities for stakeholders. However, companies must navigate cost barriers, safety concerns, and competitive pressures to sustain long-term growth in this dynamic and rapidly evolving market.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.